510 related articles for article (PubMed ID: 28119496)
1. Treatment of Pulmonary Arterial Hypertension Using Initial Combination Therapy of Bosentan and Iloprost.
Han X; Zhang Y; Dong L; Fang L; Chai Y; Niu M; Yu Y; Liu L; Yang X; Qu S; Li S
Respir Care; 2017 Apr; 62(4):489-496. PubMed ID: 28119496
[TBL] [Abstract][Full Text] [Related]
2. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
McLaughlin VV; Benza RL; Rubin LJ; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubenfire M; Seeger W
J Am Coll Cardiol; 2010 May; 55(18):1915-22. PubMed ID: 20430262
[TBL] [Abstract][Full Text] [Related]
3. Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial.
Vizza CD; Jansa P; Teal S; Dombi T; Zhou D
BMC Cardiovasc Disord; 2017 Sep; 17(1):239. PubMed ID: 28874133
[TBL] [Abstract][Full Text] [Related]
4. Sildenafil add-on therapy in paediatric pulmonary arterial hypertension, experiences of a national referral centre.
Douwes JM; Roofthooft MT; Van Loon RL; Ploegstra MJ; Bartelds B; Hillege HL; Berger RM
Heart; 2014 Feb; 100(3):224-30. PubMed ID: 24390161
[TBL] [Abstract][Full Text] [Related]
5. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.
Mathai SC; Girgis RE; Fisher MR; Champion HC; Housten-Harris T; Zaiman A; Hassoun PM
Eur Respir J; 2007 Mar; 29(3):469-75. PubMed ID: 17079256
[TBL] [Abstract][Full Text] [Related]
6. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension.
McLaughlin VV; Oudiz RJ; Frost A; Tapson VF; Murali S; Channick RN; Badesch DB; Barst RJ; Hsu HH; Rubin LJ
Am J Respir Crit Care Med; 2006 Dec; 174(11):1257-63. PubMed ID: 16946127
[TBL] [Abstract][Full Text] [Related]
7. Successful switch from long-term intravenous iloprost to non-invasive combination therapy in idiopathic pulmonary arterial hypertension.
Halank M; Kolditz M; Opitz C; Hoeffken G; Ewert R
Wien Klin Wochenschr; 2006 Feb; 118(1-2):54-9. PubMed ID: 16489527
[TBL] [Abstract][Full Text] [Related]
8. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension.
McLaughlin V; Channick RN; Ghofrani HA; Lemarié JC; Naeije R; Packer M; Souza R; Tapson VF; Tolson J; Al Hiti H; Meyer G; Hoeper MM
Eur Respir J; 2015 Aug; 46(2):405-13. PubMed ID: 26113687
[TBL] [Abstract][Full Text] [Related]
9. Successful therapy of bosentan-refractory pulmonary arterial hypertension (PAH) with inhalative iloprost.
Ahmadi-Simab K; Lamprecht P; Gross WL
Clin Exp Rheumatol; 2005; 23(3):402-3. PubMed ID: 15971433
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.
Launay D; Sitbon O; Le Pavec J; Savale L; Tchérakian C; Yaïci A; Achouh L; Parent F; Jais X; Simonneau G; Humbert M
Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974
[TBL] [Abstract][Full Text] [Related]
11. Addition of sildenafil in patients with pulmonary arterial hypertension with inadequate response to bosentan monotherapy.
Porhownik NR; Al-Sharif H; Bshouty Z
Can Respir J; 2008; 15(8):427-30. PubMed ID: 19107243
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
Johnson RF; Loyd JE; Mullican AL; Fink CA; Robbins IM
J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478
[TBL] [Abstract][Full Text] [Related]
13. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension.
Hoeper MM; Leuchte H; Halank M; Wilkens H; Meyer FJ; Seyfarth HJ; Wensel R; Ripken F; Bremer H; Kluge S; Hoeffken G; Behr J
Eur Respir J; 2006 Oct; 28(4):691-4. PubMed ID: 17012628
[TBL] [Abstract][Full Text] [Related]
14. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
Chen YF; Jowett S; Barton P; Malottki K; Hyde C; Gibbs JS; Pepke-Zaba J; Fry-Smith A; Roberts J; Moore D
Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849
[TBL] [Abstract][Full Text] [Related]
15. Rapid transition from inhaled iloprost to inhaled treprostinil in patients with pulmonary arterial hypertension.
Bourge RC; Tapson VF; Safdar Z; Benza RL; Channick RN; Rosenzweig EB; Shapiro S; White RJ; McSwain CS; Gotzkowsky SK; Nelsen AC; Rubin LJ
Cardiovasc Ther; 2013 Feb; 31(1):38-44. PubMed ID: 22970909
[TBL] [Abstract][Full Text] [Related]
16. Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy.
Seyfarth HJ; Pankau H; Hammerschmidt S; Schauer J; Wirtz H; Winkler J
Chest; 2005 Aug; 128(2):709-13. PubMed ID: 16100158
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study.
Kemp K; Savale L; O'Callaghan DS; Jaïs X; Montani D; Humbert M; Simonneau G; Sitbon O
J Heart Lung Transplant; 2012 Feb; 31(2):150-8. PubMed ID: 22138355
[TBL] [Abstract][Full Text] [Related]
18. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects.
Sitbon O; Beghetti M; Petit J; Iserin L; Humbert M; Gressin V; Simonneau G
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():25-31. PubMed ID: 16919007
[TBL] [Abstract][Full Text] [Related]
19. Directing therapy in pulmonary arterial hypertension using a target 6 min walk distance.
Porhownik NR; Myers R; Bshouty Z
Can Respir J; 2013; 20(2):111-5. PubMed ID: 23616968
[TBL] [Abstract][Full Text] [Related]
20. [Clinical and hemodynamic characteristics and possibilities for therapy in patients with severe (functional class IV) pulmonary arterial hypertension associated with diffuse connective tissue diseases].
Nikolaeva EV; Yudkina NN; Kurmukov IA; Novikova DS; Markelova EI; Volkov AV
Ter Arkh; 2015; 87(5):24-32. PubMed ID: 26155616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
